EGFR and neoplasm: As epidermal growth factor receptor (EGFR) is a key tumour driver and one of the main targets in the successful treatment of NSCLC (3, 4), and as T790M and L858R mutations have been related to the acquisition of resistance to EGFR tyrosine kinase inhibitors in the clinical setting (30), we decided to use H1299, which is EGFR wild type, and H1975, which presents the indicated mutations in EGFR, for the in vitro studies.